Reply to the Letter to the Editor ‘Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer’ by A. Okines and N. Turner
- Resource Type
- Correspondence
- Source
- In
Annals of Oncology July 2022 33(7):739-740 - Subject
- Language
- ISSN
- 0923-7534